Gentamicin Injection, Solution
Product Images NDC 51662-1508

This is a description of a medication. The medication is Gentamicin Injection which is a 20 mL multiple dose vial containing 40 mg/mL of Gentamicin. It is intended for either Intramuscular or Intravenous use and must be diluted before intravenous use. The product is NDC 63323-010-20 and it is recommended to use Rx only. The remaining text appears to be random numbers and characters and does not provide any useful information.*

This is a description of Gentamicin Injection, USP which is a medication used for IM or IV use. It is provided in a 20mL vial containing 800mg/20mL (40mg/mL) of the drug. The product has a National Drug Code (NDC) of 51662-1508-2, Lot number of 123456, and an expiration date of 2030-01-01. The medication must be diluted for IV use and the usual dosage should be obtained from the insert. The insert of the product contains warnings and precautions which should be read by the user. The product should be stored at a controlled room temperature. The original manufacturer's NDC was 63323-010-20. It is manufactured by HF Acquisition Co., LLC in Mukilteo, WA 98275.*

Gentamicin Injection is a sterile solution that is used for intravenous or intramuscular administration. It comes in a strength of 800mg/20mL in a box of 25 vials. Each vial contains 40mg/mL of Gentamicin Sulfate, and it must be diluted before use. The recommended dosage is available in the insert, and patients treated with this injection should be closely monitored due to its potential toxicity. This injection should be stored at a controlled room temperature of 20° to 25°C (68° to 77°F). The manufacturer is HF Acquisition Co., LLC, located in Mukilteo, WA, and the NDC is 63323-010-20.*

This text contains information about the potential toxicity associated with the use of aminoglycosides, with a focus on gentamicin injection. It warns of potential nephrotoxicity and neurotoxicity, particularly in patients with impaired renal function or who receive high doses or prolonged therapy. The text advises close monitoring of renal and eighth cranial nerve function, including periodic examination of urine and serum creatinine levels, and suggests obtaining audiograms in high-risk patients. Serum concentrations of aminoglycosides should also be monitored to avoid toxicity. The text warns against concurrent use of other potentially nephrotoxic or neurotoxic drugs and advises caution for advanced age and dehydration. It also cautions against concurrent or sequential use of gentamicin with certain diuretics, and warns of potential fetal harm when administered to pregnant women.*

This is a table displaying minimum inhibitory concentrations (mcg/mL) and zone diameters (mm) of different organisms such as Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis. The purpose of this table is likely for quality control measures in a laboratory or research setting.*

This text is a product information sheet for a medication with various product codes, strengths, and packaging options. The medication is available in 80 mg per 2 mL or 800 mg per 20 mL concentrations, with each vial containing 40 mg per mL. The medication is sold in units of 25 and comes in a multiple dose vial packaging.*